Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

CADD522 is an inhibitor of RUNX family transcription factor 2 (RUNX2) binding to DNA.1 It inhibits RUNX2 binding to osteoblast-specific element 2 (OSE2) oligonucleotides in a cell-free assay, as well as inhibits RUNX2 enrichment on matrix metalloproteinase-13 (MMP-13) promoters in MCF-7 cells when used at concentrations ranging from 100 to 1,000 nM. CADD522 (50 µM) decreases clonogenic survival in a panel of nine breast cancer cell lines. It decreases the expression of the RUNX2 target genes and metastasis markers MMP-13 and VEGF in ectopic RUNX2-expressing T47D-RUNX2 and MCF-7-RUNX2 breast cancer cells. CADD522 (20 mg/kg, i.p.) reduces tumor volume and incidence in the MMTV-PyMT transgenic mouse model of breast cancer.
WARNING This product is not for human or veterinary use.
1. Characterization of CADD522, a small molecule that inhibits RUNX2-